GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Current Ratio
中文

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Current Ratio : 2.51 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Biomarin Pharmaceutical's current ratio for the quarter that ended in Dec. 2023 was 2.51.

Biomarin Pharmaceutical has a current ratio of 2.51. It generally indicates good short-term financial strength.

The historical rank and industry rank for Biomarin Pharmaceutical's Current Ratio or its related term are showing as below:

BMRN' s Current Ratio Range Over the Past 10 Years
Min: 2.08   Med: 3.59   Max: 5.93
Current: 2.51

During the past 13 years, Biomarin Pharmaceutical's highest Current Ratio was 5.93. The lowest was 2.08. And the median was 3.59.

BMRN's Current Ratio is ranked worse than
62.87% of 1554 companies
in the Biotechnology industry
Industry Median: 3.795 vs BMRN: 2.51

Biomarin Pharmaceutical Current Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Current Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 4.76 4.16 4.67 2.51

Biomarin Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.67 4.75 4.94 2.54 2.51

Competitive Comparison of Biomarin Pharmaceutical's Current Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Current Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Current Ratio falls into.



Biomarin Pharmaceutical Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Biomarin Pharmaceutical's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=2956.088/1177.024
=2.51

Biomarin Pharmaceutical's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2956.088/1177.024
=2.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (NAS:BMRN) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Biomarin Pharmaceutical Current Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Headlines

From GuruFocus

AMERIPRISE FINANCIAL INC Buys 4, Sells 1 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-18-2023